Medical News

RSS

Today's OpEds: The challenge of medicare spending; Two views of Massachussets; Regulating premiums

Health reform can be assessed from the perspective of four groups that collectively include most Americans. For those who are now in Medicaid or who are uninsured, reform will be a major gain. For those who obtain health insurance in the individual and small-group markets, reform should bring improvements. For those who have health insurance from midsize- and large-group insurers, reform will bring little change. Finally, for Medicare beneficiaries, reform promises to bring positive change.

23 Jul 2010

Call for greater support in mental health services for children

As support for funds for mental ailments mounts, a coalition of mental health experts are lobbying for greater support for mental health services for children. The coalition comprises The Royal Australian and New Zealand College of Psychiatrists; the Australian Psychological Society; NIFTeY (National Investment for the Early Years); the Australian Infant, Child, Adolescent and Family Mental Health Association; the Australian Association of Infant Mental Health, and the Australian Child and Adolescent Trauma, Loss and Grief Network.

22 Jul 2010

New HIV drug on the block

Johnson and Johnson’s experimental HIV drug rilpivirine or TMC278, a non-nucleoside reverse transcriptase inhibitor (NNRTI), is being developed for use in combination therapy for treating the human immunodeficiency virus (HIV) that causes AIDS. Two clinical trials with the drug has shown that although its effectiveness was same as the existing anti-HIV drugs, its side effects were fewer. On the flip side nearly twice as many patients failed to respond to treatment with the new drug.

22 Jul 2010

Three toxins in food identified as triggers to gluten intolerance: study

Coeliac disease cause by intolerance to gluten present in food and drinks like bread, pasta, cereals, biscuits and beer commonly affects many people all over the world. This affects 1 percent of all people in UK, especially women. Patients are advised to stay away from gluten to prevent damage to their intestines. In spite of this in five years most patients develop problems in their intestines. A gluten free diet is also difficult to maintain. Possible symptoms include diarrhoea, nausea and vomiting, recurrent stomach pain, tiredness, headaches, weight loss and mouth ulcers. These may be mild, moderate or severe in different individuals.

22 Jul 2010

Drugs can save African infants' lives

Researchers at the University of Sydney have found the combined intake of iron-folic acid supplements with World Health Organisation (WHO)-endorsed anti-malarial drugs during pregnancy could reduce early infant mortality in sub-Saharan Africa by a quarter.

22 Jul 2010

Researchers share nanotechnology knowledge

InForm, a AU$2.7 million EU-funded project involving world-leading research institutionsincluding the University of Sydney,hosted its first conference, 'NanoFormulation2010', in June at Stockholm University.

22 Jul 2010

Agfa HealthCare's IMPAX HeartStation enables rapid diagnosis of 15-lead ECG studies when compared to 12-lead ECG studies at Western Maryland Regional Medical Center

Agfa HealthCare, a leading provider of diagnostic imaging and healthcare IT solutions, today announces that Western Maryland Regional Medical Center's recent upgrade to the newest version of IMPAX HeartStation ECG Management System has helped enable the rapid diagnosis and treatment of patients with posterior wall heart attacks. The Cumberland-based hospital is using the recently released features of IMPAX HeartStation to digitally review and archive 15-lead ECG studies.

22 Jul 2010

Sigma-Aldrich second-quarter sales increase 6% to $554 million

Commenting on second quarter 2010 performance, Chairman, President and CEO Jai Nagarkatti said: "Our earnings for the second quarter of 2010 continued the strong performance achieved in this year's first quarter. We are very pleased with this performance that drove our increase in diluted EPS for the first half of 2010 to 18%. Consistent with our first quarter 2010 experience, conditions were favorable in several of our markets.

22 Jul 2010

Tibotec reports Phase 3 trial results of TMC278 vs. EFV in treatment-naive HIV-1-infected adults

Tibotec Pharmaceuticals announced today results from two pivotal Phase 3, double-blind, randomized clinical trials comparing the efficacy, safety and tolerability of its investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine) versus efavirenz (EFV), each administered once daily with a nucleoside/nucleotide background regimen in treatment-naive, HIV-1-infected adults.

22 Jul 2010

LabCorp second-quarter revenues increase 4.2% to $1,238.4 million

Laboratory Corporation of America® Holdings today announced results for the quarter ended June 30, 2010.

22 Jul 2010

Achillion nominates ACH-2928 NS5A clinical candidate for treatment of HCV

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced the nomination of a lead clinical candidate in its fourth proprietary program against hepatitis C virus (HCV) infection. The candidate, ACH-2928, is an NS5A inhibitor that in preclinical studies has demonstrated excellent potency against HCV RNA replication, as well as good pharmacokinetic and safety profiles.

22 Jul 2010

Bristol-Myers Squibb second-quarter net sales increase 2% to $4.8 billion

Bristol-Myers Squibb Company today reported results for the second quarter of 2010 which featured data on key marketed and investigational compounds in its oncology, diabetes and cardiovascular franchises, and growth in sales and EPS. The company also confirmed guidance for 2010 and minimum guidance for non-GAAP EPS in 2013.

22 Jul 2010

MedeAnalytics, Health Net enter agreement to provide healthcare performance management solutions

MedeAnalytics, a leading provider of healthcare performance management solutions, announced that it has entered into a multi-year agreement with Health Net, Inc. to provide performance management solutions for Health Net's health plan operations and Medicare products. The solutions will enhance Health Net's current data analytics capabilities and include Medical Management Analytics, Provider Network Management Analytics and Operations Performance Management.

22 Jul 2010

Baxter second-quarter global sales increase 2% to $3.2 billion

Baxter International Inc. today announced its financial results for the second quarter of 2010, reporting earnings in line with the company's previously issued guidance of $0.90 to $0.93 per diluted share.

From Baxter International Inc. 22 Jul 2010

Mylan enters settlement agreement with Forest Laboratories, Merz Pharmaceuticals for Namenda

Mylan Inc. today announced that it has entered into settlement and license agreements with Forest Laboratories and Merz Pharmaceuticals related to Namenda® Tablets, 5 mg and 10 mg, known generically as Memantine Hydrochloride (HCl) Tablets.

22 Jul 2010

Tarsa completes enrollment in Phase III ORACAL trial for postmenopausal osteoporosis

Tarsa Therapeutics, Inc. today announced progress in the ORACAL trial of its oral calcitonin product for the treatment of postmenopausal osteoporosis. The company has completed patient enrollment in this multinational, randomized, double-blind, placebo-controlled Phase III trial designed to enroll approximately 550 patients. In addition, Tarsa announced that the independent Data Monitoring Committee (DMC) for the ORACAL trial has completed two separate safety reviews of patient data and recommended that the trial proceed as planned.

22 Jul 2010

3M second-quarter global sales increase 17.7% to $6.7 billion

3M today reported record second-quarter earnings of $1.54 per share on sales of $6.7 billion. Sales and per-share earnings increased 17.7 percent and 37.5 percent, respectively, versus the second quarter of 2009. Excluding special items recorded in the second quarter of 2009, earnings per share rose 28.3 percent.

22 Jul 2010

Dr. Reddy reports $257 million revenue from global generics in first-quarter fiscal 2011

Dr. Reddy's Laboratories Ltd. today announced its unaudited financial results for the quarter ended June 30, 2010 under International Financial Reporting Standards (IFRS).

22 Jul 2010

Merrimack, sanofi-aventis initiate dosing in MM-121 and exemestane combination Phase 2 breast cancer study

Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today that the first patient has received an initial dose in a Phase 2 randomized double blind clinical study combining MM-121 with exemestane (Aromasin®) in breast cancer patients.

22 Jul 2010

Zimmer second-quarter net sales increase 3.7% to $1.06 billion

Zimmer Holdings, Inc. today reported financial results for the quarter ended June 30, 2010. The Company reported second quarter net sales of $1.06 billion, an increase of 3.7% reported and 3.3% constant currency over the second quarter of 2009. Diluted earnings per share for the quarter were $0.82 reported and $1.09 adjusted, an increase of 9.0% adjusted over the prior year period.

22 Jul 2010

Medical News

Today's OpEds: The challenge of medicare spending; Two views of Massachussets; Regulating premiums

Call for greater support in mental health services for children

New HIV drug on the block

Three toxins in food identified as triggers to gluten intolerance: study

Drugs can save African infants' lives

Researchers share nanotechnology knowledge

Agfa HealthCare's IMPAX HeartStation enables rapid diagnosis of 15-lead ECG studies when compared to 12-lead ECG studies at Western Maryland Regional Medical Center

Sigma-Aldrich second-quarter sales increase 6% to $554 million

Tibotec reports Phase 3 trial results of TMC278 vs. EFV in treatment-naive HIV-1-infected adults

LabCorp second-quarter revenues increase 4.2% to $1,238.4 million

Achillion nominates ACH-2928 NS5A clinical candidate for treatment of HCV

Bristol-Myers Squibb second-quarter net sales increase 2% to $4.8 billion

MedeAnalytics, Health Net enter agreement to provide healthcare performance management solutions

Baxter second-quarter global sales increase 2% to $3.2 billion

Mylan enters settlement agreement with Forest Laboratories, Merz Pharmaceuticals for Namenda

Tarsa completes enrollment in Phase III ORACAL trial for postmenopausal osteoporosis

3M second-quarter global sales increase 17.7% to $6.7 billion

Dr. Reddy reports $257 million revenue from global generics in first-quarter fiscal 2011

Merrimack, sanofi-aventis initiate dosing in MM-121 and exemestane combination Phase 2 breast cancer study

Zimmer second-quarter net sales increase 3.7% to $1.06 billion

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News